Vascular dementia
Disease11 papers6 findings
- Humans11
Interventions
1Renin-angiotensin system inhibitors
no changein humans1HR 0.74
1 study
Renin-angiotensin system inhibitors
no changein humans1HR 0.74
Renin-angiotensin system inhibitors have no effect on vascular dementia in humans (HR 0.74, 95% CI 0.50-1.11).
Humansin adults with hypertensionmedian follow-up of 516 days
RAS inhibitors linked to lower dementia risk than CCBs · Drugs & aging · 28 Sep 2026
Upstream
1PAM activity
no changein humans1
1 study
PAM activity
no changein humans1
PAM activity has no effect on vascular dementia in humans.
Humansmean follow-up of 4.75 ± 1.3 yearsn = 4,543
Reduced peptide amidation links to higher Alzheimer's risk · Alzheimer's research & therapy · 28 Sep 2026
Associations
4Delirium
upin humans1HR 2.76
1 study
Delirium
upin humans1HR 2.76
Delirium raises the risk of vascular dementia in humans (HR 2.76 (95% CI 1.45-5.24)).
Humansin traumatic brain injury patients after propensity score matching2 years
Delirium after traumatic brain injury links to dementia risk · European journal of clinical investigation · 1 Oct 2026
Alcohol use disorder
upin humans1
1 study
Alcohol use disorder
upin humans1
Alcohol use disorder raises the risk of vascular dementia in humans (3.96 [3.44-4.56]).
Humansfemales
Alcohol use disorder links to higher dementia risk in women · medRxiv · 29 Sep 2026 · Preprint
GLP-1 receptor agonists
upin humans1RR 1.56
1 study
GLP-1 receptor agonists
upin humans1RR 1.56
GLP-1 receptor agonists raise the risk of vascular dementia in humans (RR 1.56, 95% CI 1.39-1.76).
Humanstype 2 diabetes on metformin5-year
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs · Diabetes & vascular disease research · 29 Sep 2026
Hypertension
upin humans1OR 2.72
1 study
Hypertension
upin humans1OR 2.72
Hypertension raises the risk of vascular dementia in humans (OR 2.72, 95% CI 1.66-4.45).
Humans
Global, Regional and National burden of dementia attributable to metabolic dysregulation from 1990 to 2021, with projections of burden to 2050: An analysis of the global burden of disease study 2021 · Diabetes & metabolic syndrome · 23 Sep 2026
Latest
11Delirium after traumatic brain injury links to dementia risk
In matched patients, post-injury delirium was tied to a higher two-year composite risk of dementia, vascular dementia, and Alzheimer's disease (hazard…In matched patients, post-injury delirium was tied to a higher two-year composite risk of dementia, vascular dementia, and Alzheimer's disease (hazard ratio 2.47).
Statins cut Alzheimer's risk but raise other dementia risks
A Mendelian randomization analysis found total cholesterol mediated 93.91% of statins' effect on overall dementia and 84.37% on dementia in…A Mendelian randomization analysis found total cholesterol mediated 93.91% of statins' effect on overall dementia and 84.37% on dementia in Alzheimer's disease.
COVID-19 tied to higher dementia risk in older adults with diabetes
Among patients aged 65 and older with type 2 diabetes, dementia developed in 3.25% of COVID-19 patients versus 2.75% of matched uninfected controls.Among patients aged 65 and older with type 2 diabetes, dementia developed in 3.25% of COVID-19 patients versus 2.75% of matched uninfected controls.
Alcohol use disorder links to higher dementia risk in women
Women with alcohol use disorder had a hazard ratio of 3.73 for all-cause dementia compared to controls, rising to 10.68 before age 70.Women with alcohol use disorder had a hazard ratio of 3.73 for all-cause dementia compared to controls, rising to 10.68 before age 70.
Reduced peptide amidation links to higher Alzheimer's risk
In 4,543 adults, each standard deviation drop in amidation enzyme activity raised incident Alzheimer's risk with an adjusted hazard ratio of 2.30.In 4,543 adults, each standard deviation drop in amidation enzyme activity raised incident Alzheimer's risk with an adjusted hazard ratio of 2.30.
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Older adults taking GLP-1 agonists showed higher risks of Alzheimer's disease (RR 1.33) and all-cause mortality (RR 1.11) than those on SGLT2…Older adults taking GLP-1 agonists showed higher risks of Alzheimer's disease (RR 1.33) and all-cause mortality (RR 1.11) than those on SGLT2 inhibitors.
RAS inhibitors linked to lower dementia risk than CCBs
Incidence of all-cause dementia was 1.26 per 1000 person-years with RAS inhibitors versus 1.89 with calcium channel blockers (HR 0.68).Incidence of all-cause dementia was 1.26 per 1000 person-years with RAS inhibitors versus 1.89 with calcium channel blockers (HR 0.68).